BR122020005056A2 - - Google Patents
Info
- Publication number
- BR122020005056A2 BR122020005056A2 BR122020005056A BR122020005056A BR122020005056A2 BR 122020005056 A2 BR122020005056 A2 BR 122020005056A2 BR 122020005056 A BR122020005056 A BR 122020005056A BR 122020005056 A BR122020005056 A BR 122020005056A BR 122020005056 A2 BR122020005056 A2 BR 122020005056A2
- Authority
- BR
- Brazil
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005-153508 | 2005-05-26 | ||
| JP2005153508 | 2005-05-26 | ||
| PCT/JP2006/310571 WO2006126681A1 (ja) | 2005-05-26 | 2006-05-26 | 医薬品組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR122020005056A2 true BR122020005056A2 (US20080242721A1-20081002-C00022.png) | 2010-11-23 |
| BR122020005056A8 BR122020005056A8 (pt) | 2022-11-22 |
| BR122020005056B1 BR122020005056B1 (pt) | 2023-01-10 |
Family
ID=37452103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122020005056-0A BR122020005056B1 (pt) | 2005-05-26 | 2006-05-26 | Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona) |
| BRPI0611409A BRPI0611409B8 (pt) | 2005-05-26 | 2006-05-26 | preparação oral compreendendo lurasidona |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0611409A BRPI0611409B8 (pt) | 2005-05-26 | 2006-05-26 | preparação oral compreendendo lurasidona |
Country Status (22)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006123678A1 (ja) * | 2005-05-18 | 2006-11-23 | Dainippon Sumitomo Pharma Co., Ltd. | ドロキシドパを含有する安定な錠剤 |
| DK1884242T3 (da) * | 2005-05-26 | 2013-05-06 | Dainippon Sumitomo Pharma Co | Farmaceutisk sammensætning omfattende lurasidon |
| EP2251012A4 (en) * | 2008-02-11 | 2013-03-06 | Dainippon Sumitomo Pharma Co | TABLET HAVING ENHANCED ELUTING PROPERTIES |
| WO2009151072A1 (ja) * | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
| WO2010038695A1 (ja) * | 2008-09-30 | 2010-04-08 | 大洋薬品工業株式会社 | 圧縮成型製剤およびその製造方法 |
| AU2010249615B2 (en) | 2009-05-19 | 2013-07-18 | Celgene Corporation | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| US9469630B2 (en) * | 2010-10-18 | 2016-10-18 | Sumitomo Dainippon Pharma Co., Ltd. | Sustained-release formulation for injection |
| WO2012063246A1 (en) * | 2010-11-11 | 2012-05-18 | Mapi Pharma Ltd. | Amorphous form of lurasidone hydrochloride |
| WO2012107890A2 (en) * | 2011-02-10 | 2012-08-16 | Ranbaxy Laboratories Limited | Crystalline forms of lurasidone hydrochloride |
| US9433620B2 (en) * | 2011-05-13 | 2016-09-06 | Cadila Healthcare Limited | Pharmaceutical compositions of lurasidone |
| US8981095B2 (en) | 2011-07-28 | 2015-03-17 | Mapi Pharma Ltd. | Intermediate compounds and process for the preparation of lurasidone and salts thereof |
| CN102911169B (zh) * | 2011-08-02 | 2015-05-06 | 上海医药工业研究院 | 一种卢拉西酮的制备方法 |
| WO2013061338A1 (en) | 2011-08-24 | 2013-05-02 | Cadila Healthcare Limited | Pharmaceutical compositions of silodosin |
| CN103446071B (zh) * | 2012-05-29 | 2017-12-19 | 江苏豪森药业集团有限公司 | 一种口服片剂及其制备方法和用途 |
| CN102688210A (zh) * | 2012-06-21 | 2012-09-26 | 李兴惠 | 鲁拉西酮的药物组合物和制备方法 |
| CN102688209A (zh) * | 2012-06-21 | 2012-09-26 | 李兴惠 | 鲁拉西酮片和制备方法 |
| CN103536568B (zh) * | 2012-07-12 | 2016-12-07 | 成都康弘药业集团股份有限公司 | 一种含有鲁拉西酮的口腔崩解片及其制备方法 |
| CN103006661B (zh) * | 2012-12-06 | 2015-02-18 | 江苏先声药物研究有限公司 | 一种含有盐酸鲁拉西酮的制剂及其制备方法 |
| US20150157628A1 (en) * | 2013-12-11 | 2015-06-11 | Saravanan Kannusamy | Pharmaceutical compositions of Lurasidone and Process for preparation thereof |
| WO2016012898A1 (en) * | 2014-07-25 | 2016-01-28 | Lupin Limited | Oral pharmaceutical composition of lurasidone |
| CN104606133A (zh) * | 2015-01-07 | 2015-05-13 | 万特制药(海南)有限公司 | 鲁拉西酮口服混悬液及其制备方法 |
| WO2016139683A2 (en) * | 2015-03-05 | 2016-09-09 | Jubilant Generics Limited | Pharmaceutical compositions of lurasidone and process for preparing the same |
| DE102016205950A1 (de) * | 2016-04-08 | 2017-10-12 | Dietrich Seidel | Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute |
| WO2018083117A1 (en) * | 2016-11-02 | 2018-05-11 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Solid oral pharmaceutical compositions of lurasidone hydrochloride |
| CN108567758A (zh) * | 2017-03-08 | 2018-09-25 | 湖南洞庭药业股份有限公司 | 盐酸鲁拉西酮片剂及其制备方法 |
| CN107854445A (zh) * | 2017-12-17 | 2018-03-30 | 佛山市弘泰药物研发有限公司 | 一种盐酸鲁拉西酮分散片及其制备方法 |
| CN107875122A (zh) * | 2017-12-17 | 2018-04-06 | 佛山市弘泰药物研发有限公司 | 一种盐酸鲁拉西酮自微乳制剂及其制备方法 |
| CN107854446A (zh) * | 2017-12-19 | 2018-03-30 | 佛山市弘泰药物研发有限公司 | 一种盐酸鲁拉西酮口崩片及其制备方法 |
| SG11202008233WA (en) | 2018-02-28 | 2020-09-29 | Sumitomo Dainippon Pharma Co Ltd | Aqueous suspension pharmaceutical preparation with controlled dissolution |
| US20210177197A1 (en) | 2018-04-10 | 2021-06-17 | Z-Catering Mitte Gmbh | Device for heating food preserved in packaging units and for group catering |
| WO2019199134A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 약제학적 조성물 |
| WO2022042646A1 (zh) * | 2020-08-26 | 2022-03-03 | 浙江华海药业股份有限公司 | 盐酸鲁拉西酮组合物及其制备方法 |
| AT17300U3 (de) * | 2020-12-03 | 2022-02-15 | G L Pharma Gmbh | Feste orale pharmazeutische Zusammensetzung |
| EP4268816A1 (en) * | 2020-12-23 | 2023-11-01 | Sumitomo Pharma Co., Ltd. | Oral solid preparation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600579A (en) * | 1983-06-07 | 1986-07-15 | Mallinckrodt, Inc. | N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same |
| US4551177A (en) | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
| US4609675A (en) | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
| US4837031A (en) | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
| US5047246A (en) | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| US5104648A (en) | 1989-02-02 | 1992-04-14 | Mallinckrodt Specialty Chemicals Company | High ibuprofen content granulations |
| US4911921A (en) | 1989-02-02 | 1990-03-27 | Mallinckrodt, Inc. | High ibuprofen content granulations |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| AU701042B2 (en) | 1995-02-28 | 1999-01-21 | Aventisub Llc | Pharmaceutical composition for piperidinoalkanol compounds |
| JP4022269B2 (ja) * | 1995-05-26 | 2007-12-12 | 協和醗酵工業株式会社 | 医薬組成物 |
| AU740299B2 (en) | 1997-10-20 | 2001-11-01 | Dainippon Sumitomo Pharma Co., Ltd. | Fast-dissolving pharmaceutical composition |
| JP4063386B2 (ja) | 1998-01-29 | 2008-03-19 | キッセイ薬品工業株式会社 | 速放性経口医薬品組成物 |
| US6150366A (en) | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
| EA005291B1 (ru) * | 1999-03-31 | 2004-12-30 | Янссен Фармацевтика Н.В. | Применение предварительно желатинированного крахмала в композиции с контролируемым высвобождением |
| US6586617B1 (en) | 1999-04-28 | 2003-07-01 | Sumitomo Chemical Takeda Agro Company, Limited | Sulfonamide derivatives |
| WO2001076557A1 (fr) * | 2000-04-10 | 2001-10-18 | Sumitomo Pharmaceuticals Co., Ltd. | Preparations a liberation prolongee |
| DK1327440T5 (da) * | 2000-09-22 | 2009-09-07 | Dainippon Sumitomo Pharma Co | Orale pr parater med gunstige nedbrydningsegenskaber |
| JP4250423B2 (ja) | 2001-03-19 | 2009-04-08 | 大日本住友製薬株式会社 | アリール置換脂環式化合物及びそれを含有する医薬組成物 |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| JP4745661B2 (ja) * | 2002-08-22 | 2011-08-10 | 大日本住友製薬株式会社 | 統合失調症治療剤 |
| BR0313773A (pt) | 2002-08-30 | 2005-06-21 | Pharmacia Corp | Formas farmacêuticas de dosagem sólida exibindo perfil de liberação de fármaco reprodutìvel |
| JPWO2004078173A1 (ja) * | 2003-02-05 | 2006-06-08 | 塩野義製薬株式会社 | 溶出性の改善された錠剤 |
| TR201910177T4 (tr) | 2003-09-12 | 2019-08-21 | Amgen Inc | Bir sinakalset HCl içeren hızlı çözünme formülasyonu. |
| KR20060126688A (ko) | 2003-12-09 | 2006-12-08 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 약물-함유 입자 및 그 입자를 함유하는 고형 제제 |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| DK1884242T3 (da) | 2005-05-26 | 2013-05-06 | Dainippon Sumitomo Pharma Co | Farmaceutisk sammensætning omfattende lurasidon |
-
2006
- 2006-05-26 DK DK06746900.7T patent/DK1884242T3/da active
- 2006-05-26 SI SI200631567T patent/SI1884242T1/sl unknown
- 2006-05-26 CN CN2006800182234A patent/CN101184489B/zh not_active Expired - Fee Related
- 2006-05-26 MX MX2007014872A patent/MX2007014872A/es active IP Right Grant
- 2006-05-26 KR KR1020077027270A patent/KR101380088B1/ko active IP Right Grant
- 2006-05-26 KR KR1020137027051A patent/KR101552033B1/ko active IP Right Grant
- 2006-05-26 ES ES11181100.6T patent/ES2535478T3/es active Active
- 2006-05-26 AU AU2006250340A patent/AU2006250340C1/en active Active
- 2006-05-26 US US11/919,678 patent/US8729085B2/en active Active
- 2006-05-26 JP JP2007517921A patent/JP4733120B2/ja active Active
- 2006-05-26 WO PCT/JP2006/310571 patent/WO2006126681A1/ja active Application Filing
- 2006-05-26 CA CA2606510A patent/CA2606510C/en active Active
- 2006-05-26 EP EP20110181100 patent/EP2422783B1/en active Active
- 2006-05-26 BR BR122020005056-0A patent/BR122020005056B1/pt active IP Right Grant
- 2006-05-26 PT PT67469007T patent/PT1884242E/pt unknown
- 2006-05-26 ES ES06746900T patent/ES2408687T3/es active Active
- 2006-05-26 BR BRPI0611409A patent/BRPI0611409B8/pt active IP Right Grant
- 2006-05-26 EP EP06746900.7A patent/EP1884242B1/en active Active
- 2006-05-26 DK DK11181100.6T patent/DK2422783T3/en active
- 2006-05-26 CN CN2010105647842A patent/CN102048734B/zh not_active Expired - Fee Related
- 2006-05-26 RU RU2007148997A patent/RU2398586C3/ru not_active Application Discontinuation
- 2006-05-26 PL PL06746900T patent/PL1884242T3/pl unknown
-
2008
- 2008-03-03 HK HK08102367.3A patent/HK1108379A1/xx unknown
-
2011
- 2011-03-18 JP JP2011061211A patent/JP5285105B2/ja active Active
-
2013
- 2013-05-14 CY CY20131100384T patent/CY1114118T1/el unknown
-
2014
- 2014-02-18 US US14/183,283 patent/US8883794B2/en active Active
- 2014-09-15 HU HUS1400051C patent/HUS1400051I1/hu unknown
- 2014-09-16 NL NL300690C patent/NL300690I2/nl unknown
- 2014-09-16 FR FR14C0069C patent/FR14C0069I2/fr active Active
- 2014-09-18 LU LU92550C patent/LU92550I2/xx unknown
- 2014-09-18 CY CY2014039C patent/CY2014039I2/el unknown
- 2014-10-10 US US14/512,189 patent/US9555027B2/en active Active
-
2015
- 2015-06-08 US US14/733,204 patent/US9907794B2/en active Active
-
2018
- 2018-02-06 US US15/889,893 patent/US20180161322A1/en not_active Abandoned
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: SUMITOMO PHARMA CO., LTD. (JP) |
|
| B25G | Requested change of headquarter approved |
Owner name: SUMITOMO PHARMA CO., LTD. (JP) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |